Risk and Return Analysis of Top 5 Mid-Cap Pharmaceutical Companies in India of NSE

The Indian pharmaceutical sector plays a crucial role in the nation's economy, contributing significantly to healthcare advancement and drug manufacturing. Mid-cap pharmaceutical companies, in particular, present a promising investment opportunity due to their potential for growth. However, these firms also carry higher risks, including regulatory challenges, market competition, and financial volatility. This study focuses on evaluating the risk-return profiles of the top five mid-cap pharmaceutical companies in India listed on the NSE: Aurobindo Pharma, Glenmark Pharmaceuticals, Alkem Laboratories, Lupin Ltd., and Divi’s Laboratories. The research aims to address the increasing need to understand whether the returns offered by these companies are sufficient to justify the associated risks for investors and portfolio managers. The primary objectives include analyzing historical returns, calculating financial metrics like beta and standard deviation, and providing investment recommendations based on the findings. A quantitative and descriptive research approach was employed, utilizing data from financial platforms and statistical tools to assess the companies' performance over a specified period. The results indicate that while all five companies outperformed the NSE, they exhibited higher volatility. Glenmark Pharmaceuticals led in absolute returns but showed significant volatility, while Divi’s Laboratories demonstrated stability with lower risk, appealing to risk-averse investors. The outcomes provide critical insights into the trade-offs between risk and return, aiding investors in making informed decisions about mid-cap pharmaceutical investments.